DBV Technologies S.A. (NASDAQ:DBVT) Sees Significant Decrease in Short Interest

DBV Technologies S.A. (NASDAQ:DBVTGet Free Report) saw a significant decline in short interest during the month of May. As of May 31st, there was short interest totalling 332,800 shares, a decline of 36.2% from the May 15th total of 521,800 shares. Based on an average daily volume of 72,000 shares, the short-interest ratio is presently 4.6 days.

DBV Technologies Stock Performance

NASDAQ:DBVT traded down $0.02 during trading on Thursday, reaching $1.04. The company’s stock had a trading volume of 13,638 shares, compared to its average volume of 54,805. The firm has a market cap of $99.82 million, a price-to-earnings ratio of -1.25 and a beta of 0.69. The firm has a 50 day moving average of $1.22 and a 200-day moving average of $1.53. DBV Technologies has a 12 month low of $0.84 and a 12 month high of $4.52.

DBV Technologies (NASDAQ:DBVTGet Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.16. The firm had revenue of $1.41 million during the quarter, compared to the consensus estimate of $3.20 million. DBV Technologies had a negative return on equity of 56.76% and a negative net margin of 530.89%. Equities research analysts forecast that DBV Technologies will post -1.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in DBVT. Yiheng Capital Management L.P. grew its stake in shares of DBV Technologies by 6.2% during the 1st quarter. Yiheng Capital Management L.P. now owns 5,568,909 shares of the company’s stock worth $4,172,000 after acquiring an additional 327,345 shares during the period. Optiver Holding B.V. grew its stake in shares of DBV Technologies by 595.2% during the 3rd quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock worth $374,000 after acquiring an additional 235,337 shares during the period. Finally, Cowen AND Company LLC bought a new position in shares of DBV Technologies during the 4th quarter worth $49,000. Institutional investors own 71.74% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on DBVT. StockNews.com assumed coverage on DBV Technologies in a research report on Friday, June 7th. They set a “hold” rating on the stock. HC Wainwright lowered their price target on DBV Technologies from $20.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th.

Get Our Latest Stock Report on DBV Technologies

DBV Technologies Company Profile

(Get Free Report)

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

Featured Stories

Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.